Calliditas Therapeutics AB (publ) (CALT) Competitors $40.00 0.00 (0.00%) As of 03/27/2025 Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsTrendsBuy This Stock CALT vs. PTCT, RNA, ACLX, OGN, ZLAB, RARE, SWTX, AKRO, ALVO, and RYTMShould you be buying Calliditas Therapeutics AB (publ) stock or one of its competitors? The main competitors of Calliditas Therapeutics AB (publ) include PTC Therapeutics (PTCT), Avidity Biosciences (RNA), Arcellx (ACLX), Organon & Co. (OGN), Zai Lab (ZLAB), Ultragenyx Pharmaceutical (RARE), SpringWorks Therapeutics (SWTX), Akero Therapeutics (AKRO), Alvotech (ALVO), and Rhythm Pharmaceuticals (RYTM). These companies are all part of the "pharmaceutical products" industry. Calliditas Therapeutics AB (publ) vs. PTC Therapeutics Avidity Biosciences Arcellx Organon & Co. Zai Lab Ultragenyx Pharmaceutical SpringWorks Therapeutics Akero Therapeutics Alvotech Rhythm Pharmaceuticals Calliditas Therapeutics AB (publ) (NASDAQ:CALT) and PTC Therapeutics (NASDAQ:PTCT) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, media sentiment, valuation, community ranking, dividends and analyst recommendations. Does the MarketBeat Community favor CALT or PTCT? PTC Therapeutics received 541 more outperform votes than Calliditas Therapeutics AB (publ) when rated by MarketBeat users. Likewise, 61.87% of users gave PTC Therapeutics an outperform vote while only 55.10% of users gave Calliditas Therapeutics AB (publ) an outperform vote. CompanyUnderperformOutperformCalliditas Therapeutics AB (publ)Outperform Votes2755.10% Underperform Votes2244.90% PTC TherapeuticsOutperform Votes56861.87% Underperform Votes35038.13% Is CALT or PTCT more profitable? Calliditas Therapeutics AB (publ) has a net margin of -30.18% compared to PTC Therapeutics' net margin of -50.32%. PTC Therapeutics' return on equity of 0.00% beat Calliditas Therapeutics AB (publ)'s return on equity.Company Net Margins Return on Equity Return on Assets Calliditas Therapeutics AB (publ)-30.18% -212.04% -27.96% PTC Therapeutics -50.32%N/A -16.44% Do analysts prefer CALT or PTCT? Calliditas Therapeutics AB (publ) currently has a consensus target price of $39.25, indicating a potential downside of 1.88%. PTC Therapeutics has a consensus target price of $64.00, indicating a potential upside of 16.38%. Given PTC Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe PTC Therapeutics is more favorable than Calliditas Therapeutics AB (publ).Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Calliditas Therapeutics AB (publ) 0 Sell rating(s) 5 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00PTC Therapeutics 2 Sell rating(s) 4 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.53 Does the media favor CALT or PTCT? In the previous week, PTC Therapeutics had 8 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 8 mentions for PTC Therapeutics and 0 mentions for Calliditas Therapeutics AB (publ). PTC Therapeutics' average media sentiment score of 1.10 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that PTC Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Calliditas Therapeutics AB (publ) Neutral PTC Therapeutics Positive Do institutionals and insiders believe in CALT or PTCT? 2.8% of Calliditas Therapeutics AB (publ) shares are held by institutional investors. 2.2% of Calliditas Therapeutics AB (publ) shares are held by insiders. Comparatively, 5.5% of PTC Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has preferable earnings and valuation, CALT or PTCT? Calliditas Therapeutics AB (publ) has higher revenue and earnings than PTC Therapeutics. Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than PTC Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCalliditas Therapeutics AB (publ)$1.60B0.74-$43.96M-$1.85-21.62PTC Therapeutics$806.78M5.38-$626.60M-$4.73-11.63 Which has more risk and volatility, CALT or PTCT? Calliditas Therapeutics AB (publ) has a beta of 1.77, meaning that its stock price is 77% more volatile than the S&P 500. Comparatively, PTC Therapeutics has a beta of 0.66, meaning that its stock price is 34% less volatile than the S&P 500. SummaryPTC Therapeutics beats Calliditas Therapeutics AB (publ) on 13 of the 19 factors compared between the two stocks. Remove Ads Get Calliditas Therapeutics AB (publ) News Delivered to You Automatically Sign up to receive the latest news and ratings for CALT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CALT vs. The Competition Export to ExcelMetricCalliditas Therapeutics AB (publ)Pharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.19B$6.92B$5.65B$8.06BDividend YieldN/A2.72%4.57%4.01%P/E Ratio-21.627.2023.1619.03Price / Sales0.74226.01386.8193.17Price / CashN/A65.6738.1634.64Price / Book37.746.476.914.33Net Income-$43.96M$141.90M$3.20B$247.06M7 Day PerformanceN/A-3.20%-2.30%-0.37%1 Month PerformanceN/A-5.64%2.86%-3.85%1 Year Performance90.39%-7.47%10.51%1.27% Calliditas Therapeutics AB (publ) Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CALTCalliditas Therapeutics AB (publ)N/A$40.00flat$39.25-1.9%N/A$1.19B$1.60B-21.62180PTCTPTC Therapeutics3.4714 of 5 stars$57.03-0.2%$64.00+12.2%+86.8%$4.50B$806.78M-9.601,410Positive NewsRNAAvidity Biosciences2.3139 of 5 stars$33.30+8.0%$66.69+100.3%+32.0%$4.00B$10.90M-11.56190ACLXArcellx2.2486 of 5 stars$72.48+4.5%$108.46+49.6%-2.8%$3.98B$107.94M-102.0880Positive NewsOGNOrganon & Co.4.7795 of 5 stars$15.35-0.3%$20.80+35.5%-21.1%$3.96B$6.40B4.6110,000News CoveragePositive NewsZLABZai Lab2.4045 of 5 stars$35.67+1.7%$47.37+32.8%+123.5%$3.91B$398.99M-12.881,950Analyst ForecastPositive NewsGap UpRAREUltragenyx Pharmaceutical4.4361 of 5 stars$39.36+0.5%$91.71+133.0%-16.9%$3.64B$560.23M-6.211,276Analyst ForecastNews CoveragePositive NewsSWTXSpringWorks Therapeutics2.3806 of 5 stars$48.51-2.8%$73.20+50.9%-5.2%$3.64B$191.59M-13.94230Positive NewsAKROAkero Therapeutics4.2598 of 5 stars$45.08-0.3%$76.29+69.2%+78.2%$3.59BN/A-12.0230Insider TradePositive NewsGap UpALVOAlvotech2.0209 of 5 stars$11.56-0.1%$18.00+55.7%-18.3%$3.49B$391.87M-6.251,026Earnings ReportNews CoverageRYTMRhythm Pharmaceuticals4.4103 of 5 stars$53.72+3.2%$69.46+29.3%+28.0%$3.40B$130.13M-12.41140Analyst Revision Remove Ads Related Companies and Tools Related Companies PTC Therapeutics Alternatives Avidity Biosciences Alternatives Arcellx Alternatives Organon & Co. Alternatives Zai Lab Alternatives Ultragenyx Pharmaceutical Alternatives SpringWorks Therapeutics Alternatives Akero Therapeutics Alternatives Alvotech Alternatives Rhythm Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CALT) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredDo this Before Elon's Reveal on April 23rdElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredTrump’s Treasure Map [Pic inside]We were shown this map by former Presidential Advisor, Jim Rickards, one of the most politically connected men...Paradigm Press | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Calliditas Therapeutics AB (publ) Please log in to your account or sign up in order to add this asset to your watchlist. Share Calliditas Therapeutics AB (publ) With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CALT Stock Free CALT Stock Alerts